Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Xbrane Biopharma AB ( (SE:XBRANE) ) is now available.
Xbrane Biopharma AB has outlined the procedure for shareholders to appoint a proxy to represent and vote their shares at the annual general meeting scheduled for 5 May 2026. Shareholders must complete and sign a proxy form, with additional documentation required when a legal entity is involved.
The company clarifies that submitting a proxy form does not replace the separate requirement to formally notify participation in the meeting, which must be done according to the notice of the general meeting. Completed proxy forms should be sent by regular mail or email to the specified law firm contact well in advance, and shareholders who do not wish to vote by proxy are not required to submit the form.
The notice also directs shareholders to Euroclear’s online privacy notice for information on how personal data related to the meeting and proxy process will be handled and protected. This guidance ensures regulatory compliance and transparency in handling shareholder data and voting rights during the annual general meeting process.
The most recent analyst rating on (SE:XBRANE) stock is a Sell with a SEK6.00 price target. To see the full list of analyst forecasts on Xbrane Biopharma AB stock, see the SE:XBRANE Stock Forecast page.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a Sweden-based biopharmaceutical company. It is focused on the development and commercialization of biosimilar drugs, aiming to offer cost-effective alternatives to existing biologic treatments in international markets.
Average Trading Volume: 54,361
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK124.1M
For a thorough assessment of XBRANE stock, go to TipRanks’ Stock Analysis page.